Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
about
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationAdvances in targeted therapies and new promising targets in esophageal cancerThe efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials.HER-2 overexpression and survival in colorectal cancer: a meta-analysisMicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylationEfficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system reviewPrognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancerSubgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancerSignificant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience.Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence.The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair.Survival after failure of first-line chemotherapy in advanced gastric cancer patients: differences between Japan and the rest of the world.Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.Correlation of Trastuzumab-based Treatment with Clinical Characteristics and Prognosis in HER2-Positive Gastric and gastroesophageal Junction Cancer: A retrospective single center analysis.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer.HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial).Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.
P2860
Q26765941-3F0C6D4F-F627-4EB3-A351-39D8FBAEBB5AQ26825957-FDB59021-A1D3-4537-BEFB-04379976F795Q33437413-44282E52-3674-435A-AF7E-49C930B0BAC1Q33979049-E72137FA-7A0A-40F2-8AB8-657047940DC3Q34699904-36B578AC-206D-448C-B52C-FFD01FF9749CQ36134904-F5419737-24DA-4501-8FB0-75F51A37172DQ36303653-506248D4-DF03-49ED-B0CA-46131740F054Q36408890-982564E4-04BD-428E-B510-CF2872E8F117Q36450457-D6821CF1-8D41-469A-8A61-76718C6F900FQ36467394-C4CE0D76-27E9-4C1C-93D5-7E1480D31FB8Q36801203-7EA6A0DE-B16E-408B-A303-F0776A1E762AQ36832238-15E28419-373E-499F-9FDC-CF6A0B02860DQ37342452-03DCE263-2817-4927-8BF1-B51A821B0028Q37632143-261BF4AA-36F6-4F83-BD92-B8A1253492E7Q38140697-829311BF-1B0D-4F57-BF91-7DAF702DCB5AQ38401300-EA3188F2-B568-4392-BE17-80E1F59FA20DQ38931710-D6696D83-B388-49C0-847E-1D1A5D8B4A45Q38942944-0F9B87E3-CFA2-4857-89B7-BDCAB7685F16Q39109847-A2730C18-4FA3-40B7-9AB5-3762A5304B2BQ39220127-BE80585B-816B-48B1-AAC8-A092A8C7E591Q39234296-14E10423-4724-4A85-8F1A-876C77C1CA3BQ47178340-F374D210-B84E-4AA5-83AA-4013B081A718Q47190729-4E53269D-6DA5-48D2-BFD9-1EB4607A2582Q47402625-A6C9B0FF-4807-4509-AE9C-6C00CA942748Q47838777-17D2B9C5-7648-4246-962C-F40347D3093EQ48124426-225B13EE-2641-4517-ADF4-E6386A274D8DQ50449083-C8B3417A-2249-4907-B29C-7879EDE5B29EQ53298150-39FF6370-C785-45E4-BB1E-2C5DB13622D2Q54218339-C259FB4C-F690-4435-BA77-18DA6BA35201Q54326192-EA729F25-30D4-4E7D-93A7-FF469CF33DABQ54340137-E58302C8-6E28-45B9-9403-2AA28CEB6F34Q54469155-6737E97C-0265-4355-A980-78583F7EF93F
P2860
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Efficacy of trastuzumab in Jap ...... r Gastric Cancer (ToGA) study.
@ast
Efficacy of trastuzumab in Jap ...... r Gastric Cancer (ToGA) study.
@en
type
label
Efficacy of trastuzumab in Jap ...... r Gastric Cancer (ToGA) study.
@ast
Efficacy of trastuzumab in Jap ...... r Gastric Cancer (ToGA) study.
@en
prefLabel
Efficacy of trastuzumab in Jap ...... r Gastric Cancer (ToGA) study.
@ast
Efficacy of trastuzumab in Jap ...... r Gastric Cancer (ToGA) study.
@en
P2093
P2860
P1433
P1476
Efficacy of trastuzumab in Jap ...... r Gastric Cancer (ToGA) study.
@en
P2093
Akira Sawaki
Atsushi Ohtsu
Atsushi Satoh
Eishi Baba
Hiroya Takiuchi
Kensei Yamaguchi
Kiyohiko Hatake
Narikazu Boku
Takao Tamura
Takashi Abe
P2860
P2888
P304
P356
10.1007/S10120-011-0118-1
P577
2011-12-17T00:00:00Z